Truist raised the firm’s price target on Edwards Lifesciences (EW) to $87 from $82 and keeps a Hold rating on the shares. The company had a positive day at TCT2025, with late-breaking 7-year results averting a worst case outcome, which should at a minimum offer reassurance/confidence to TAVR surgeons in their existing low-risk algorithm patient treatment, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Hold Rating Amidst Stable TAVR vs. SAVR Trial Outcomes
- Positive Outlook on Edwards Lifesciences Reinforced by PARTNER 3 Study Results
- Positive Long-Term Outlook for Edwards Lifesciences’ TAVR Procedures Reinforces Buy Rating
- Positive Outlook for Edwards Lifesciences Reinforced by Long-Term TAVR Data
- EW Earnings this Week: How Will it Perform?